focus -WSS

focus

author：knowledge 2025-09-06 02:15:03 - browse：2785

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Researchers on aging grapple with how to calculate biological age

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

Lasker Awards 2023: Winners in biomedical research

Thermo Fisher plant for manufacturing gene therapies to expand

Biotech lab space demand falls sharply

Ukraine and a new approach to mental health in war

Making AI in medicine accessible to smaller, and rural hospitals

knowledge

focus

hotspot

How one medical school became remarkably diverse

CDC's new outbreak response network to include Northeastern

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Hepatitis C has a cure — but many Americans still lack access to it

How Vertex's cystic fibrosis drug is changing patients' lives

United colonoscopy coverage change 'may cost lives,' doctors say

Study: AI not yet building 'n

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: possible new ALS drug, artificial wombs

hotspot

Drug for rare kidney disease narrowly misses mark in clinical trial

Why are Kaiser Permanente staff considering a strike?

Sanofi strikes deal with Novavax, boosting the vaccine maker

Intarcia’s device

Readout LOUD podcast: What to know about H5N1 bird flu

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

hotspot

Wikipedia

focus